This trial is evaluating whether tapinarof cream, 1% will improve 1 primary outcome and 4 secondary outcomes in patients with Dermatitis. Measurement will happen over the course of Baseline to Week 8.
This trial requires 400 total participants across 2 different treatment groups
This trial involves 2 different treatments. Tapinarof Cream, 1% is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"Eczema, infantile is a chronic viral disease in which symptoms usually begin in the first 2 years of life. There is no cure. Treatment is symptomatic. Vaccination against rubella and hepatitis B is important." - Anonymous Online Contributor
"Eczema and the other inflammatory skin disorders seem to be multifactorial. However eczema and sepsis are the most common cause of death in children and adolescents with eczema, and thus, sepsis and eczema are both listed as health priorities." - Anonymous Online Contributor
"When diagnosed, eczema was present in 70 to 80% of patients. Eczema was characterized by itchy skin rash which was aggravated during exposure to irritants (e.g. sweat, soaps, detergents, and cosmetics) and more easily scratched like that occurs during diaper changing. All eczema patients presented an association of eczema with respiratory symptoms (cough, wheezing) and with the allergic rhinitis. Eczema in infants was characterized by the presence of other symptoms like eczema-like skin rash and atopic diseases, most importantly [eosinophilic esophagitis|asthma] and allergic rhinitis." - Anonymous Online Contributor
"Eczema and infantile eczema are typically treated with corticosteroids and antihistamines. There appears to be a need to reconsider the use of anticonvulsants to reduce the risk of seizures on corticosteroid therapy." - Anonymous Online Contributor
"In addition to having a measurable anti-inflammatory effect, tapinarof provided the additional benefit of improved patient compliance with the treatment to induce complete skin healing." - Anonymous Online Contributor
"For the treatment of the children the study did not support the use of tapinarof cream, as it resulted in slightly more itchiness and more pruritus." - Anonymous Online Contributor
"Tapinarof 1%, cream (0.02%) is an adequate treatment regimen in the management of moderate-to-severe to extensive perineal eczema (atrophic perineal dermatitis) associated with significant perineal inflammation. Tapinarof 1%, cream is well tolerated, very beneficial and a very useful addition to the existing therapy." - Anonymous Online Contributor
"Findings from a recent study suggest that there may exist an idiopathic eczema in some patients with severe lesions and in an infantile onset form in patients with a milder skin lesion and a late onset eczema." - Anonymous Online Contributor
"Tapinarof has been studied in a double-blind, randomized clinical trial and a prospective study. These trials are not double-blinded studies because individuals receiving the tapinarof cream were aware of their treatment assignment. For the first trial, the investigators included the placebo control arm for the primary endpoint; for the second trial, the investigators excluded the placebo control arm. These trials indicated that tapinarof has no effect on either the severity or disease status of Eczema, atopic dermatitis, atopic eczema of infancy, or atopic dermatitis of infancy. The studies were also not limited to infants only. Tapinarof application may be beneficial in children and adults." - Anonymous Online Contributor
"There have been very few new discoveries since 1990. There was one new drug that was successful against eczema. The treatments for eczema that have been developed do not represent a perfect solution because of insufficient knowledge, the problem that most people in the field share about the diseases pathophysiology (aetiology) still needs to be solved because currently available drugs have no benefit for all of those who suffer from eczema." - Anonymous Online Contributor